| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/08/2005 | US20050197396 Crystal of amino acid ester salt and process for producing the same |
| 09/08/2005 | US20050197395 Compositions and methods for body weight management |
| 09/08/2005 | US20050197394 antifatigue agents containing diacylglycerol as an active ingredient; glycerides |
| 09/08/2005 | US20050197393 Pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease |
| 09/08/2005 | US20050197392 O-desmethylvenlafaxine and methods of preparing and using the same |
| 09/08/2005 | US20050197391 Thiol ester compositions and processes for making and using same |
| 09/08/2005 | US20050197390 Thiol ester compositions and processes for making and using same |
| 09/08/2005 | US20050197388 Crystalline composition containing escitalopram |
| 09/08/2005 | US20050197386 Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them |
| 09/08/2005 | US20050197385 Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
| 09/08/2005 | US20050197384 water or organic solvent extract of mycelium of Antrodia Camphorata; has central cholinergic agonism, hepatoprotection, anti-inflammation or anti-tumor activity |
| 09/08/2005 | US20050197383 Quaternary ammonium compounds and their use as anti-tussive agents |
| 09/08/2005 | US20050197381 methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof |
| 09/08/2005 | US20050197380 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands |
| 09/08/2005 | US20050197379 neuroprotective and neuroregenerative compositions; produced by actinomycete strains |
| 09/08/2005 | US20050197378 Cationic substituted benzofurans as antimicrobial agents |
| 09/08/2005 | US20050197377 Diarylimidazoles, substituted with another aromatic ring and one or more carboxylic acids, esters or amides, e.g., 3-[5-Benzo[1,3]dioxol-5-yl-4-(2,5-dichloro-phenyl)-1H-imidazol-2-yl]-2-(3-chloro-phenyl)-acrylic acid; treatment of conditions such as pain, drug dependence, and psychological disorders |
| 09/08/2005 | US20050197376 Concomitant drugs |
| 09/08/2005 | US20050197375 Use of benzimidazole analogs in the treatment of cell proliferation |
| 09/08/2005 | US20050197374 New long acting beta-2 agonists and their use as medicaments |
| 09/08/2005 | US20050197373 Substituted fused bicyclic amines as modulators of chemokine receptor activity |
| 09/08/2005 | US20050197372 Use of valsartan or its metabolite to inhibit platelet aggregation |
| 09/08/2005 | US20050197371 Urea derivatives as PDGFR modulators |
| 09/08/2005 | US20050197369 Compounds useful for the synthesis of (+)-discodermolide and methods therefor |
| 09/08/2005 | US20050197368 Novel compounds as inhibitors of cell proliferation and viral infections |
| 09/08/2005 | US20050197367 Novel bicyclic compounds as modulators of androgen receptor function and method |
| 09/08/2005 | US20050197366 and a synergistic mixture of 4,5-dichloro-2-n-octyl-4-isothiazolin-3-one, 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one, having enhanced activity against various strains of microorganisms; microbiocides |
| 09/08/2005 | US20050197365 Diamino thiazoloindan derivatives and their use |
| 09/08/2005 | US20050197364 Amide compounds as ion channel ligands and uses thereof |
| 09/08/2005 | US20050197363 Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| 09/08/2005 | US20050197362 Preventives/remedies for urinary disturbance |
| 09/08/2005 | US20050197361 Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| 09/08/2005 | US20050197360 3-Beta-(p-Chlorophenyl)-2-beta-(3-(p-methylphenyl)-oxazol-5-yl)-tropane or a salt, especially the HCl salt; useful as substitute drugs for psychostimulant abuse and as neurotransmitter re-uptake inhibitors; for treating Parkinson's Disease, depression, and eating, bipolar, sexual, and AD disorders |
| 09/08/2005 | US20050197359 Bicyclic modulators of androgen receptor function |
| 09/08/2005 | US20050197358 Administration of N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide to induce cytokine biosynthesis or as a viricide or anticarcinogenic agent |
| 09/08/2005 | US20050197356 Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents |
| 09/08/2005 | US20050197355 Compounds useful in preparing camptothecin derivatives |
| 09/08/2005 | US20050197353 E.g., N-[(S)-2-diphenylamino-1-(5-oxo-4,5-dihydro[1,3,4]oxadizol-2-yl)ethyl]-2-(2-methylaminopyrimidin-4-yl)-1H-indole-5-carboxamide; used for treating rheumatoid arthritis, osteoarthritis, asthma, cardiac infarction, Alzheimer's diseases, cancer diseases, atherosclerosis, etc. |
| 09/08/2005 | US20050197351 Such as 4-{N-[4-(4-methylbenzenesulfonylamido)benzyl]acetamido}-3-phenyl-2-(piperidine-1-yl)-3,4-dihydroquinazoline; for therapy of angina pectoris, high blood pressure, myocardial disease, pain and epilepsy by blocking the T-type calcium channel |
| 09/08/2005 | US20050197350 Melanin Concentrating Hormone (MCH) receptor antagonist; clinical obesity; eating disorders; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methoxy-benzamide; N-(2-chlorobenzyl)-N'-(cis-4-{[4- -(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea; pyrimidine analogs |
| 09/08/2005 | US20050197349 Pyrrolo[2,3-D]pyrimidine compounds |
| 09/08/2005 | US20050197348 Indazole derivatives as inhibitors of hormone sensitive lipase |
| 09/08/2005 | US20050197347 Crystalline form having X-Ray powder diffraction pattern with peaks at 9.4, 13.7, 14.5, 14.9, 18.1, 20.2, 22.8+-0.2 degrees 2 theta; reacting salt of ziprasidone with alkaline agent and precipitating |
| 09/08/2005 | US20050197346 Substituted heterocyclic compounds |
| 09/08/2005 | US20050197344 antiproliferative, antitumor agent; fungicide; inhibit eukaryotic cell cycle progression in M phase; rheumatoid arthritis, chronic articular rheumatism, psoriasis, diabetic retinopathy, neovascular glaucoma, retinopathy of prematurity, macular degeneration, corneal graft rejection, osteoporosis |
| 09/08/2005 | US20050197343 N-[(4-phenyl-1-piperazinyl)alkyl]-substituted heteroarene carboxamide or 2-ferrocenyl compounds; psychiatric diseases: schizophrenia , unipolar depression, disturbances of consciousness, antidepressant; neurodegenerative diseases: Parkinson's disease, attention deficit hyperactivity syndrome; drug abuse |
| 09/08/2005 | US20050197342 Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
| 09/08/2005 | US20050197341 Reducing expression of tetrahydrobiopterin (BH4) biological activity; traumatic, metabolic or toxic peripheral nerve lesions |
| 09/08/2005 | US20050197339 Di-substituted pyrrolotrizine compounds |
| 09/08/2005 | US20050197338 Substituted pyrazole urea compounds for the treatment of inflammation |
| 09/08/2005 | US20050197336 2-[4-(naphtha-2-yl-4-sulfonyl)-piperazin-1-yl]-thiazole-5-carboxylic acid hydroxyamide; antiproliferative agent; synergestic mixture with other anticarcinogenic agents; cell cycle arrest, cellular differentiation, apoptosis and reversal of the trans-formed phenotype |
| 09/08/2005 | US20050197335 Indazole-carboxamide compounds as 5-HT4 receptor agonists |
| 09/08/2005 | US20050197333 Rifamycin analogs and uses thereof |
| 09/08/2005 | US20050197331 Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production |
| 09/08/2005 | US20050197330 Heterocyclic GABAA subtype selective receptor modulators |
| 09/08/2005 | US20050197329 drugs such as 4-(4-{[amino(2-thienyl)methylidene]amino}phenyl)-N-(4-phenoxyphenyl)butanamide, used as nitric oxide synthase inhibitors and selective or non-selective traps for reactive oxygen species |
| 09/08/2005 | US20050197328 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent |
| 09/08/2005 | US20050197327 Compounds, compositions, and methods |
| 09/08/2005 | US20050197326 1,4-benzothiazin-3-ones that are optionally S-mono- or dioxygenated, quinoxazinones, quinolinones and benzapinones; peptide deformylase inhibitors, used for treating bacterial infections |
| 09/08/2005 | US20050197325 Substituted spiro azabicyclics as modulators of chemokine receptor activity |
| 09/08/2005 | US20050197323 Full or partial glucocorticosteroid replacement therapy for obstructive pulmonary bronchial diseases |
| 09/08/2005 | US20050197322 Compounds capable of binding to proteins constituting or associated with cytoskeletal elements, and their applications for the manufacture of medicaments |
| 09/08/2005 | US20050197321 Treatment of sepsis |
| 09/08/2005 | US20050197320 Phosphonate and sulfide substituted imidazole compounds; antihuman immunodeficiency viral agents |
| 09/08/2005 | US20050197319 Allergen inactivating agent |
| 09/08/2005 | US20050197316 Method of enhancing drainage of lacrimal system with purinergic receptor agonists |
| 09/08/2005 | US20050197314 Synergistic combination of immunostimulatory CpG oligonucleotides and the immunopotentiating cytokine Flt3 ligand; immunotherapy of tumors, viral infections; cancer vaccines |
| 09/08/2005 | US20050197304 Stimulating regeneration with naked DNA encoding bioactive agents; does not cause insertional mutagenesis, host immunogenicity or tissues targeting difficulties |
| 09/08/2005 | US20050197303 Storage and pH stability; tissue inflammation and infection treatment |
| 09/08/2005 | US20050197302 Organic amine salt of closantel; administered with carrier and optionally macrocyclic lactone; bioavailability, blood concentration; veterinary medicine |
| 09/08/2005 | US20050197300 Microdose therapy |
| 09/08/2005 | US20050197299 Peptidomimetic protease inhibitors |
| 09/08/2005 | US20050197291 Administering compound which blocks endothelial growth factor |
| 09/08/2005 | US20050197290 Useful in extending the in vivo circulating life of biologically active materials; bicine linker allows for the manipulation of the hydrolysis rate of the prodrug, thereby releasing the native entities at various rates in vivo as well as in vitro |
| 09/08/2005 | US20050197280 Antioxidant combination composition and use thereof |
| 09/08/2005 | US20050197265 Composition including an active cleaning combination selected from a quaternary ammonium base in combination with at least one of alkali and alkaline earth base and a strong base in combination with an oxidant; semiconductors |
| 09/08/2005 | US20050196869 Measurement using urinary catalytic iron; administering iron chelate |
| 09/08/2005 | US20050196819 Methods and compositions to lower plasma cholesterol levels |
| 09/08/2005 | US20050196813 Heterocyclic sulfonamide inhibitors of beta amyloid production |
| 09/08/2005 | US20050196793 Using aberrant expression of caudal type homeobox transcription factor 2 (CDX2) as diagnostic indicator of stomach or esophageal cell proliferative disorers |
| 09/08/2005 | US20050196512 Structured lipid containing compositions and methods with health and nutrition promoting characteristics |
| 09/08/2005 | US20050196479 Polysaccharide extract of dioscorea sp. and an orally active pharmaceutical composition comprising the same |
| 09/08/2005 | US20050196473 To increase the therapeutic index of doxorubicin, thalidomide, capecitabine, gemcitabine, or oxaliplatin; synergistic mixture of Scutellaria, Glycyrrhiza, Ziziphus and Paeonia extracts with the anticarcinogenic agents |
| 09/08/2005 | US20050196470 Method and composition for enhancing sexual desire |
| 09/08/2005 | US20050196469 Calcium in the form of a carbonate, citrate, citrate malate, gluconate, lactate, acetate, or stearate salt, vitamin D3, and folic acid or folinic acid; multi-vitamins |
| 09/08/2005 | US20050196468 Composition and method for nutritional supplement for drug abuse treatment and rehabilitation |
| 09/08/2005 | US20050196467 Treatment system including carotenoid, nicotinamide, zinc, water soluble extract of uncaria species and deterium reduced aqueous fluid and method using the same |
| 09/08/2005 | US20050196466 Process for inhibiting cell proliferation |
| 09/08/2005 | US20050196461 Treating wrinkles by ingesting a ceramide and carrier of wheat germ oil and yellow beeswax in a soft gelatin capsule; packaged nutraceutical |
| 09/08/2005 | US20050196459 Carvedilol salts, anhydrates and/or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
| 09/08/2005 | US20050196457 Controlling particle size distribution; preparing a quench liquid;pumping the first phase and the second phase through manifold that includes a plurality of static mixers to form an emulsion; polydispersity |
| 09/08/2005 | US20050196456 Controlled release particles |
| 09/08/2005 | US20050196453 Crystal particles of escitalopram oxalate with a broad particle size suitable for use in direct compression; prior to crystallization comprising at least 0.01% (w/w) of or E- Z-4-(4-dimethylamino--dimethylamino-1-(4-fluorophenyl)-but-1-enyl)-3-hydroxymethyl-benzonitrile; tablets |
| 09/08/2005 | US20050196451 Tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration |
| 09/08/2005 | US20050196450 Administering ethyl and/or isopropyl alcohol to burns and surrounding tissues; may contain ammonium hydroxide and/or bicarbonate; reducing level of cytokine, interleukin, and/or tumor necrosis factor; wound healing agents |
| 09/08/2005 | US20050196445 Edible microcrystalline cellulose and carrageenan coating composition |
| 09/08/2005 | US20050196443 Pulsatile release compositions and methods for enhanced intestinal drug absorption |
| 09/08/2005 | US20050196440 Mucoadhesive drug delivery devices and methods of making and using thereof |
| 09/08/2005 | US20050196439 Process for co-spray drying agents with dry silicified MCC |
| 09/08/2005 | US20050196437 Hard capsules |